

Healthcare-Associated Infections Caused by *Mycolicibacterium neoaurum*

Kate Shapiro, Shane J. Cross, Ted H. Morton, Hiroto Inaba,
Ashley Holland, Francisca R. Fasipe, Elisabeth E. Adderson



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/eid>; and (4) view/print certificate. For CME questions, see page XXX.

NOTE: It is Medscape's policy to avoid the use of Brand names in accredited activities. However, in an effort to be as clear as possible, the use of brand names should not be viewed as a promotion of any brand or as an endorsement by Medscape of specific products.

Release date: July 14, 2023; Expiration date: July 14, 2024

Learning Objectives

Upon completion of this activity, participants will be able to:

- Assess the demographic and clinical characteristics of *Mycolicibacterium neoaurum* infection, based on a case report of a child with leukemia and catheter-related bloodstream infection and a case series of 36 previously reported episodes of *M. neoaurum* infection
- Evaluate the diagnosis and management of *Mycolicibacterium neoaurum* infection, based on a case report of a child with leukemia and catheter-related bloodstream infection and a case series of 36 previously reported episodes of *M. neoaurum* infection
- Determine the clinical implications of demographic and clinical characteristics, diagnosis, and management of *Mycolicibacterium neoaurum* infection, based on a case report of a child with leukemia and catheter-related bloodstream infection and a case series of 36 previously reported episodes of *M. neoaurum* infection

CME Editor

Susan Zunino, PhD, Technical Writer/Editor, Emerging Infectious Diseases. *Disclosure: Susan Zunino, PhD, has no relevant financial relationships.*

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. *Disclosure: Laurie Barclay, MD, has no relevant financial relationships.*

Authors

Kate Shapiro, MD; Shane J. Cross, PharmD; Ted H. Morton, PharmD; Hiroto Inaba, PhD; Ashley Holland, MSN; Francisca R. Fasipe, MD; and Elisabeth E. Adderson, MD.

Author affiliations: St. Jude Children's Research Hospital, Memphis, Tennessee, USA (K. Shapiro, S.J. Cross, T.H. Morton, H. Inaba, A. Holland, E.E. Adderson); University of Tennessee Health Sciences Center, Memphis (S.J. Cross, T.H. Morton,

H. Inaba, E.E. Adderson); Mercy Children's Hospital, Springfield, Missouri, USA (F.R. Fasipe)

DOI: <https://doi.org/10.3201/eid2908.230007>

Mycolicibacterium neoaurum is a rapidly growing mycobacterium and an emerging cause of human infections. *M. neoaurum* infections are uncommon but likely underreported, and our understanding of the disease spectrum and optimum management is incomplete. We summarize demographic and clinical characteristics of a case of catheter-related *M. neoaurum* bacteremia in a child with leukemia and those of 36 previously reported episodes of *M. neoaurum* infection. Most infections occurred in young to middle-aged adults with serious underlying medical conditions and commonly involved medical devices. Overall, infections were not associated with severe illness or death. In contrast to other mycobacteria species, *M. neoaurum* was generally susceptible to multiple antimicrobial drugs and responded promptly to treatment, and infections were associated with good outcomes after relatively short therapy duration and device removal. Delays in identification and susceptibility testing were common. We recommend using combination antimicrobial drug therapy and removal of infected devices to eradicate infection.

Comprehensive phylogenetic and genomic studies support the division of the genus *Mycobacterium* into 5 main clades: the emended genus *Mycobacterium*, *Mycolicibacter* gen. nov., *Mycolicibacillus* gen. nov., *Mycolicibacterium* gen. nov., and *Mycobacteroides* gen. nov. (1). *Mycolicibacterium* spp. include rapidly growing mycobacteria (RGM) that are not part of the *Mycobacterium abscessus* complex (i.e., *Mycobacteroides* gen. nov., which includes *M. abscessus*, *M. chelonae*, *M. franklinii*, *M. immunogenum*, and *M. saopaulense*).

Mycolicibacterium spp. are considered to have low pathogenicity, but some are associated with human infection. *Mycolicibacterium neoaurum*, originally described by Tsukamura in 1972, is derived from the Greek word for new gold because of distinctive yellow-orange colonies (2). Since its identification, increasing numbers of case reports and small case series of invasive *M. neoaurum* infections have been described. Infections are likely underrecognized because many laboratories do not identify all mycobacteria at the species level. Bacteremia might also be missed or isolates inappropriately dismissed as contaminants because mycobacteria might require longer culture incubation than conventional bacterial pathogens, and they are ubiquitous in the environment.

Although best practices for treating infections caused by more commonly reported RGM species are now recognized, our understanding of disease spectra and best infection management strategies for rarer RGM species, such as *M. neoaurum*, remains incomplete. Therefore, to improve clinical awareness of

M. neoaurum, we summarized demographic and clinical characteristics of 36 previously reported episodes and report an additional case of *M. neoaurum* infection.

Methods

We obtained demographic and clinical characteristics of the patient in the reported case from health information records. We searched PubMed and Embase (<https://www.embase.com>) databases by using the terms *neoaurum*, *Mycobacterium neoaurum*, and *Mycolicibacterium neoaurum*. We cited cases that reported individual clinical data and were published in any year or language. Patient characteristics were summarized by using descriptive statistics. Analyses were performed by using Stata version 16.1 software (StataCorp LLC).

Results

Case Report

A 21-month-old boy with low-risk B cell acute lymphoblastic leukemia (ALL) in remission was treated by using the St. Jude Children's Research Hospital TOTAL Therapy Study 17 protocol (ClinicalTrials.gov identifier NCT03117751), which is similar to the low-risk arm of the TOTAL Therapy Study 16 protocol (identifier NCT00549848) (3). In brief, remission induction consists of prednisone, vincristine, daunorubicin, and pegylated asparaginase, then cyclophosphamide, cytarabine, and mercaptopurine. Consolidation therapy consists of 4 courses of high-dose methotrexate and mercaptopurine. Continuation therapy consists of 120 weeks of mercaptopurine, dexamethasone, vincristine, and methotrexate interrupted by 2 reinduction cycles with dexamethasone, vincristine, and pegylated asparaginase. Triple intrathecal therapy with methotrexate, dexamethasone, and cytarabine was provided to control leukemia in the central nervous system.

During week 13 of continuation therapy, the patient had a fever of 103°F, cough, coryza, anorexia, and diarrhea and was hospitalized 1 day after onset of those signs and symptoms. His medical history was remarkable because of episodes of mucositis associated with chemotherapy, a recent respiratory syncytial virus upper respiratory tract infection, and distant placement of a subcutaneous port (SCP) for intravenous access. He received trimethoprim/sulfamethoxazole (TMP/SMX) for *Pneumocystis pneumonia* prophylaxis. He lived with his family in an urban area, and no history of difficulties accessing his SCP or erythema, discharge, or tenderness at the SCP insertion site had been observed. His physical

examination was unremarkable except for mild pallor. His blood leukocyte count was 10.9×10^3 cells/ μL (reference range $6.0\text{--}17.0 \times 10^3$ cells/ μL), consisting of 77% neutrophils, 9% lymphocytes (absolute lymphocyte count 0.97×10^3 cells/ μL [reference range $1.20\text{--}4.00 \times 10^3$ cells/ μL]), and 13% monocytes. He was mildly anemic; hemoglobin level was 10.7 g/dL (reference range 11.3–12.3 g/dL). Serum C-reactive protein was elevated at 10.7 mg/L (reference range <5.0 mg/dL), aspartate aminotransferase level was 136 U/L (reference range 10–50 U/L), and alanine aminotransferase level was 520 U/L (reference range ≤ 50 U/L). Serum bilirubin was within reference range. A respiratory PCR panel was positive for respiratory syncytial virus.

The patient's symptoms resolved overnight, and he was discharged. One bacteria species was isolated after a 5-day incubation of blood cultures obtained from the patient's SCP at hospital admission by using the BacT/ALERT automated microbial detection system (bioMérieux). The organism was initially reported as a gram-positive coccobacillus but stained weakly, prompting acid-fast bacillus (AFB) staining, which gave positive results. *M. neoaurum* was identified initially by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and confirmed by 16S rRNA sequencing; both of those analyses were performed at the Mayo Clinic Laboratories (Rochester, MN, USA). The Mayo Clinic Laboratories also performed antimicrobial drug susceptibility testing by using the broth microtiter dilution method. Results were reported as MICs (in $\mu\text{g}/\text{mL}$) and interpreted according to Clinical and Laboratory Standards Institute guidelines (4).

The patient was readmitted for further bacteremia evaluation 9 days after initial blood cultures were obtained. *M. neoaurum* was again isolated from blood drawn from the SCP and catheter tip, but blood cultures obtained from a peripheral vein were sterile. Results of chest radiograph were unremarkable. We initiated empirical therapy with intravenous imipenem/cilastatin, oral azithromycin, and oral ciprofloxacin. We removed the SCP on hospital day 3, and 3 blood cultures obtained after port removal were sterile. We inserted a central catheter line peripherally on hospital day 6. Antimicrobial drug susceptibility tests showed that the *M. neoaurum* isolate was susceptible to cefoxitin, imipenem, ciprofloxacin, moxifloxacin, amikacin, tobramycin, doxycycline, TMP/SMX, and linezolid and resistant to clarithromycin. The MIC for tigecycline was $0.12 \mu\text{g}/\text{mL}$. We ultimately treated the patient with imipenem/cilastatin, azithromycin, and ciprofloxacin for 16 days, then with TMP/SMX

and ciprofloxacin for 26 days, and he remained well 15 months later.

Literature Review

We found 238 articles in the literature and included 31 reports describing 36 cases in this review (Appendix Table, <https://wwwnc.cdc.gov/EID/article/29/8/23-0007-App1.pdf>). Including the case report we described, the median age of patients was 46 (interquartile range [IQR] 25–59) years, and 19 (51%) were female. All but 1 patient had serious underlying chronic medical conditions: malignancy ($n = 13$, 35%), cardiovascular disease ($n = 9$, 24%), chronic renal insufficiency ($n = 6$, 16%), diabetes ($n = 6$, 16%), and gastrointestinal disorders ($n = 4$, 11%). Some patients had indwelling central venous catheters (CVCs) ($n = 19$, 51%) or other foreign bodies, such as prosthetic valves ($n = 3$), pacemakers ($n = 2$), peritoneal dialysis catheters ($n = 2$), hemodialysis catheter ($n = 1$), and an orthopedic external fixation device ($n = 1$).

The most common manifestation of infection was bacteremia ($n = 22$, 59%); a total of 11 patients had central line-associated bacteremia, 8 had CVC-related bacteremia, 1 had bacteremia associated with a pacemaker lead infection, and 1 had bacteremia from a hemodialysis fistula (5). Bacteremia occurred in 1 patient without a CVC who had undergone liver transplantation. Pneumonia occurred in 4 patients, 3 of whom had underlying pulmonary disease. Skin and soft tissue infections were reported in 3 patients, and postsurgical infections were found in 2 patients (a pacemaker pocket infection and infection at a pin exit site). Both patients with endocarditis had histories of intravenous drug abuse and had undergone previous mitral valve replacement. Both patients with peritonitis had indwelling peritoneal dialysis catheters. Other infections included single episodes of granulomatous meningitis and urinary tract infection.

Delays in identifying *M. neoaurum* were common. The median time to reporting positive cultures was 4.5 (IQR 1–10) days. Most isolates were identified as gram-positive or gram-variable coccobacilli or bacilli. In 1 case, AFB staining was delayed, leading to preliminary identification of the isolate as *Rhodococcus* sp. (6). In 24 cases for which the method of definitive identification was reported, investigators used chromatography ($n = 6$); matrix-assisted laser desorption/ionization time-of-flight mass spectrometry ($n = 4$); or sequencing of 16S rRNA ($n = 15$), the β subunit of RNA polymerase *ropB* gene ($n = 1$), or 65-kDa heat shock protein gene *hsp65* ($n = 8$). In 2 cases, a specific mycobacterial PCR was used for identification.

Of 21 isolates tested, all were susceptible to doxycycline, linezolid, and moxifloxacin according to the published report or Clinical and Laboratory Standards Institute broth microdilution interpretive criteria for RGM. Most isolates were susceptible to amikacin (17 of 18 isolates), ceftioxin (12 of 13), ciprofloxacin (15 of 16), imipenem (14 of 15), and meropenem (3 of 3) (Table) (6–23). Isolates were less reliably susceptible to TMP/SMX (10 of 15 isolates) and clarithromycin (7 of 15). Patients were treated with a variety of antimicrobial agents and regimens for a median duration of 6 (IQR 5–13) weeks; 3 patients received no antimicrobial drug therapy, and treatment details were not reported for 1 case. Combination antimicrobial drug therapy was used initially in 25 (74%) and, ultimately, 26 (76%) patients. Most (16 of 19) patients with CVC-associated bacteremia had their CVC removed. Infection management involving other medical devices often included device removal. However, several infections were treated only with antimicrobial drugs, including 1 of 2 cases of endocarditis, 1 of 2 infections associated with peritoneal dialysis

catheters, 1 pacemaker pocket infection, and 1 pin tract infection. The patient with meningitis died; the long-term outcome of another patient with a urinary tract infection was not reported. Otherwise, infections in all patients were cured. One patient with CVC-related bacteremia who was treated medically had a relapse that was successfully treated by CVC removal and a second course of antimicrobial drugs. The relative risk for relapse among patients with CVC-associated infections who had their CVC removed was 0.083 (95% CI 0.0041–1.6860; $p = 0.105$); the number needed to treat for 1 patient to benefit was 2.9.

Other Reports

In addition to the individual cases in this review, a case series of 4 patients with *M. neoaurum* bacteremia has been reported (24). Their median age was 54 years, and 3 were male. All 4 patients were immunocompromised (3 with hematologic malignancies, 1 with a solid tumor) but not neutropenic. Three patients were treated by catheter removal and a combination of antimicrobial drugs. In 1 case, the isolate

Table. Methods of determination and antimicrobial drug susceptibilities of isolates from the current case and published reports of healthcare-associated infections caused by *Mycolicibacterium neoaurum**

Reference	Method	Antimicrobial drug susceptibility†
Case report	Broth microdilution	Amikacin, ≤ 1 , S; ceftioxin, 4, S; ciprofloxacin, ≤ 0.12 , S; clarithromycin, 8, R; doxycycline, ≤ 0.12 , S; imipenem, 0.12, S; linezolid, ≤ 1 , S; moxifloxacin, 0.06, S; tigecycline, 0.12, no interpretation; TMP/SMX, 2/38, S
(6)	Agar dilution	Amikacin, 0.5, S; ciprofloxacin, 0.016, S; clarithromycin, 4, I; doxycycline, 0.064, S; linezolid, 0.25, S; meropenem, 0.25, S; moxifloxacin, 0.008, S; TMP/SMX, 0.25, S
(7)	Etest	Amikacin, S; clarithromycin, S; TMP/SMX, S
(8)	Disk diffusion	Amikacin, S; ceftioxin, S; doxycycline, S; imipenem, S; TMP/SMX, S
(9)	Etest	Amikacin, S; ceftioxin, S; ciprofloxacin, S; clarithromycin, S; imipenem, S; linezolid, S; TMP/SMX, R
(10)	Broth microdilution	Amikacin, S; ceftioxin, S; ciprofloxacin, S; clarithromycin, R; doxycycline, S; imipenem, S; linezolid, S; moxifloxacin, S; TMP/SMX, S
(11)	Disk diffusion	Amikacin, S; ceftioxin, S; ciprofloxacin, S; clarithromycin, R; imipenem, S; TMP/SMX, R
(12)	Broth microdilution	Amikacin, ≤ 8 , S; ceftioxin, ≤ 16 , S; ciprofloxacin, ≤ 1 , S; doxycycline, ≤ 1 , S; imipenem, ≤ 2 , S; linezolid, ≤ 1 , S; moxifloxacin, ≤ 0.5 , S; TMP/SMX, 1/19, S
(13)	Not reported	Amikacin, R; ciprofloxacin, R; imipenem, R; TMP/SMX, R
(14)	Not reported	Amikacin, ≤ 1 , S; ceftioxin, 8, S; ciprofloxacin, ≤ 0.12 , S; clarithromycin, > 4 , R; doxycycline, ≤ 0.25 , S
(14)	Not reported	Amikacin, 8, S; doxycycline, 0.5, S; linezolid, 1, S
(14)	Broth microdilution	Amikacin, 1, S; ceftioxin, 8, S; ciprofloxacin, 0.25, S; clarithromycin, 0.25, S; imipenem, 1, S; linezolid, 2, S
(15)	Not reported	Amikacin, ≤ 1 , S; ceftioxin, 8, S; ciprofloxacin, 0.25, S; clarithromycin, > 16 , R; doxycycline, 1, S; imipenem, ≤ 2 , S; linezolid, 4, S; moxifloxacin, ≤ 0.25 , S; TMP/SMX, 0.5/9.5, S
(16)	Disk diffusion	Amikacin, S; ciprofloxacin, S; doxycycline, S; imipenem, S; meropenem, S; TMP/SMX, S
(17)	Etest	Ciprofloxacin, S; clarithromycin, R; doxycycline, S; imipenem, S
(18)	Broth microdilution	Amikacin, ≤ 1.0 , S; ceftioxin, 32, I; ciprofloxacin, ≤ 0.125 , S; clarithromycin, 2, S; doxycycline, ≤ 0.125 , S; imipenem, 2, S; linezolid, < 2 , S; moxifloxacin, ≤ 0.125 , S; TMP/SMX, 16/304, R
(19)	Not reported	Amikacin, ≤ 8 , S; ceftioxin, ≤ 16 , S; ciprofloxacin, ≤ 1 , S; clarithromycin, 1, S; doxycycline, ≤ 1 , S; imipenem, < 2 , S; linezolid, ≤ 1 , S; moxifloxacin, ≤ 0.5 , S; TMP/SMX, $< 0.5/9.5$, S
(20)	Etest	Ceftioxin, 2, S; ciprofloxacin, 0.6, S; clarithromycin, 0.125, S; imipenem, 0.19, S; linezolid, 1.5, S; moxifloxacin, 0.2, S; TMP/SMX, 32, R
(21)	Broth microdilution	Amikacin, < 1 , S; ceftioxin, 8, S; clarithromycin, 2, S; imipenem, < 2 , S; linezolid, 2, S; meropenem, 2, S; moxifloxacin, ≤ 0.25 , S; TMP/SMX, 1/19, S
(22)	Disk diffusion	Amikacin, S; clarithromycin, R; ciprofloxacin, S; doxycycline, S
(23)	Etest	Imipenem, 0.12, S

*Values for each antimicrobial drug are MICs in $\mu\text{g/mL}$. Etest, bioMérieux. I, intermediate; S, sensitive; R, resistant; TMP/SMX, trimethoprim/sulfamethoxazole.

†MICs were interpreted according to broth microdilution criteria in the Clinical and Laboratory Standards Institute guidelines for rapidly growing mycobacteria (4).

was considered a contaminant and not treated. All infections were cured. In another report, 2 of 28 patients (both children) with cancer had bacteremia attributed to *M. neoaurum* (25).

Discussion

Previous reports have described *M. neoaurum* infections as primarily affecting immunocompromised persons. However, infections that we described in our case report and literature review might be more appropriately considered healthcare-associated infections, because most patients were not immunocompromised but had medical devices or had undergone invasive procedures before infections developed. In our study, 3 patients with pulmonary infections had conditions that predisposed them to anatomic lung abnormalities and infections caused by other mycobacteria species (26). Furthermore, 1 patient with a skin and soft tissue infection had a history of penetrating trauma, but 2 others with this condition did not report trauma. However, injury might not have been recalled, or *M. neoaurum* inoculation might have occurred through an unrecognized skin break. In a single-center study of cutaneous nontuberculous mycobacteria infections, histories of trauma, surgical procedure, or environmental exposure to mycobacteria were common among patients; *M. neoaurum* caused 2 of 78 infections (27). As the population of persons with chronic medical conditions increases, more *M. neoaurum* infections will likely be recognized.

We found that 1 infection in our case series occurred in a previously healthy, 25-year-old woman who showed signs of pulmonary disease that was AFB smear positive; the infecting organism was confirmed as *M. neoaurum* by 16S rRNA sequencing (18). Although this finding suggests that *M. neoaurum* might cause occasional disease in healthy persons, the patient might have had an unrecognized risk factor for mycobacterial infection, such as interferon gamma receptor 1 deficiency, which would only become apparent over time (28). The patient responded to antimicrobial drug therapy, but her long-term outcome was not reported.

One patient in our review who had several serious medical comorbidities had rapidly progressive dementia and diagnostic imaging studies suggestive of recurrent ischemic stroke (29); an autopsy revealed granulomatous meningitis. Results of conventional diagnostic microbiology were uninformative, but broad-range bacterial rDNA PCR amplified a product that was 99% homologous to *M. neoaurum* DNA. However, histopathologic stains did not reveal AFB, cultures were sterile, and the patient met criteria for

an alternative diagnosis of probable Creutzfeldt-Jacob disease, suggesting that PCR might have been falsely positive (29,30). Except for this case, all patients in our review were promptly cured of their infections, and no patient required intensive care or died. Thus, in contrast to other RGM species, *M. neoaurum* appears to have low virulence and is associated with limited illness and death (26).

M. neoaurum has been isolated from soil, tap water, fish, domesticated animals, and animal products (31–33). Infections are presumed to result from exposure of susceptible hosts to organisms in the environment (34). Nosocomial infections caused by RGM are not uncommon and are often related to contamination of medical devices, wounds, or aqueous solutions. An outbreak of *Mycobacterium mucogenicum* and *M. neoaurum* bacteremia among patients with hematologic malignancies has been reported (7). *M. mucogenicum* and other nontuberculous mycobacteria, but not *M. neoaurum*, were isolated from the hospital water system (water tanks, showers, wash basins). Environmental measures, such as cleaning or replacing fixtures, general cleaning, chlorinating the water supply, and minimizing stagnation, reduced but did not eliminate water contamination. After changes were made to protocols for the care of CVCs, however, no further cases were reported. Environmental samples from the hospital and home environment of a patient with pulmonary *M. neoaurum* infection were similarly analyzed (35). Again, other mycobacteria were isolated from these sources, but *M. neoaurum* was not identified. Therefore, additional studies will be needed to elucidate the pathogenesis and risk factors for *M. neoaurum* infection.

Delays in identifying *M. neoaurum* and obtaining susceptibility test results pose challenges to microbiologists and clinicians. The median time to initial culture positivity in this series was >4 days and as high as 10 days, which might exceed the usual incubation duration for blood cultures, leading to premature no growth determinations (6,36). Many hospital laboratories no longer routinely speciate bacteria or perform susceptibility testing, and delays in appropriate treatment might be compounded by the need to send isolates to a reference laboratory. In this case series, empirical therapy was often directed at more common RGM. In some cases, susceptibility testing was not performed, and therapy success was judged by the patient's clinical response. The quality of care for patients with RGM infections might be improved by educating laboratory personnel regarding characteristics of less commonly identified RGM, developing protocols that promote rapid identification, and

sending isolates to laboratories with specialized expertise in identification and susceptibility testing.

The optimal type and duration of antimicrobial drug therapy for *M. neoaurum* infections has not been established. *M. neoaurum* bacteria are resistant to most antituberculosis medications. In 1 study, all 46 *M. neoaurum* isolates tested were susceptible to amikacin, cefoxitin, ciprofloxacin, doxycycline, imipenem, linezolid, moxifloxacin, and TMP/SMX, but only 8% were susceptible to clarithromycin (37). Isolates in our case series were also susceptible to most tested antimicrobial drugs but less consistently than previously described (37). Of note, most reports included in our study did not describe the methodology used for testing susceptibilities or used methods that were not recommended. In particular, macrolide susceptibility might have been overestimated if prolonged incubation was not used to detect inducible macrolide resistance (38). Furthermore, whereas most *M. neoaurum* infections have responded well to therapy, a formal correlation between antimicrobial drug susceptibility and clinical outcomes has not been made. As in our case report, other clinicians have frequently used a combination of agents that often include a macrolide, a fluoroquinolone, or both. Although initial combination therapy might be desirable, $\approx 25\%$ of patients in our case series received monotherapy or were treated by device removal alone, and 1 patient with bacteremia recovered without treatment.

The ability of RGM to cause medical device infections and subsequent need for device removal to eradicate infection has been attributed in part to RGM biofilm formation (39). Not all RGM produce biofilms, however, and biofilm formation by *M. neoaurum* has not been specifically investigated (40–42). Failure to remove CVCs in patients with catheter-associated bacteremia was associated with treatment failure in our case series; however, the small number of cases precludes a precise estimate of risk. Good outcomes were reported in some cases when it was not feasible to remove devices. The ideal duration of antimicrobial drug therapy is also uncertain; ≥ 4 weeks has been recommended for patients with other RGM infections (39). For *M. neoaurum* infections described in this report, patients with bacteremia treated with antimicrobial drugs for ≤ 4 weeks had outcomes equivalent to those receiving a longer course.

RGM treatment for patients with underlying medical disorders might be challenging because of antimicrobial drug resistance, relatively high rates of adverse events, and some medications having multiple and serious drug interactions. In our case report, the patient required ongoing treatment for ALL that

included mercaptopurine, methotrexate, dexamethasone, and vincristine. The availability of a relatively large number of antimicrobial drugs to which his isolate was susceptible permitted us to continue his chemotherapy without substantial disruption. Imipenem and cilastatin do not have notable interactions with those chemotherapeutic agents. Although TMP/SMX might theoretically exacerbate myelosuppression by mercaptopurine, the combination is commonly used during ALL treatment, and we felt this treatment would be manageable. However, clarithromycin (a strong cytochrome P450 3A4 inhibitor) has potentially severe interactions with vincristine and dexamethasone and is withheld typically for a specified period before and after administration of vincristine. Ciprofloxacin used in combination with dexamethasone might increase the risk for tendinitis or tendon rupture. During ALL induction therapy, patients are usually prescribed concurrent levofloxacin (for antibacterial prophylaxis) and corticosteroids for several weeks, and we have not observed frequent or severe adverse effects (43). We believe that, with careful observation, benefits of this regimen exceeded risks in our patient.

In conclusion, we established that infections caused by the emerging RGM pathogen *M. neoaurum* occurred in patients with diverse demographic characteristics, but almost all cases were healthcare associated. In contrast to isolates of other RGM species, *M. neoaurum* isolates were generally susceptible to tested antimicrobial drugs; a notable exception was clarithromycin. We recommend using combination antimicrobial drug therapy and removal of infected devices, although a shorter treatment duration than is generally recommended for RGM might be effective for *M. neoaurum* infections. We found that delays in identification of isolates and susceptibility testing occurred, but outcomes of most infections were good.

Acknowledgments

We thank Vani Shanker for her critical review of the manuscript.

This work was supported by the American Lebanese Syrian Associated Charities.

About the Author

Dr. Shapiro earned her medical degree from the Renaissance School of Medicine at Stony Brook University in 2018 and completed pediatric residency training at Stony Brook Children's Hospital in 2021. She currently works as a clinical postdoctoral fellow at St. Jude Children's Research Hospital and Le Bonheur Children's Hospital.

References

- Gupta RS, Lo B, Son J. Phylogenomics and comparative genomic studies robustly support division of the genus *Mycobacterium* into an emended genus *Mycobacterium* and four novel genera. *Front Microbiol.* 2018;9:67. <https://doi.org/10.3389/fmicb.2018.00067>
- Tsukamura M. A new species of rapidly growing, scotochromogenic mycobacteria, *Mycobacterium neoaurum* *tsukamura* n. sp. [in Japanese]. *Med Biol.* 1972;85:229-33.
- Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. *J Clin Oncol.* 2019;37:3377-91. <https://doi.org/10.1200/JCO.19.01692>
- Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, *Nocardia* spp., and other aerobic actinomycetes, 3rd edition (M24-3E). Wayne (PA): The Institute; 2018.
- Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;49:1-45. <https://doi.org/10.1086/599376>
- Hayton ER, Koch O, Scarborough M, Sabharwal N, Drobniewski F, Bowler ICJW. Rapidly growing mycobacteria as emerging pathogens in bloodstream and device-related infection: a case of pacemaker infection with *Mycobacterium neoaurum*. *JMM Case Rep.* 2015;2:1-3. <https://doi.org/10.1099/jmmcr.0.000054>
- Baird SF, Taori SK, Dave J, Willocks LJ, Roddie H, Hanson M. Cluster of nontuberculous mycobacteremia associated with water supply in a haemato-oncology unit. *J Hosp Infect.* 2011;79:339-43. <https://doi.org/10.1016/j.jhin.2011.07.006>
- Davison MB, McCormack JG, Blacklock ZM, Dawson DJ, Tilse MH, Crimmins FB. Bacteremia caused by *Mycobacterium neoaurum*. *J Clin Microbiol.* 1988;26:762-4. <https://doi.org/10.1128/jcm.26.4.762-764.1988>
- Rubia MF, Chozas N, García-Martos P, Reyes F. *Mycobacterium neoaurum* bacteremia in an immunodepressed patient [in Spanish]. *Enferm Infecc Microbiol Clin.* 2009;27:58-9. <https://doi.org/10.1016/j.eimc.2008.02.003>
- Hawkins C, Qi C, Warren J, Stosor V. Catheter-related bloodstream infections caused by rapidly growing nontuberculous mycobacteria: a case series including rare species. *Diagn Microbiol Infect Dis.* 2008;61:187-91. <https://doi.org/10.1016/j.diagmicrobio.2008.01.004>
- Holland DJ, Chen SC, Chew WW, Gilbert GL. *Mycobacterium neoaurum* infection of a Hickman catheter in an immunosuppressed patient. *Clin Infect Dis.* 1994;18:1002-3. <https://doi.org/10.1093/clinids/18.6.1002>
- Moseley JE Jr, Thind SK. *Mycobacterium neoaurum* bloodstream infection associated with a totally implanted subclavian port in an adult with diabetes and history of colon cancer. *Case Rep Infect Dis.* 2020;2020:8878069. <https://doi.org/10.1155/2020/8878069>
- Pang L, Chen Z, Xu D, Cheng W. Case report: *Mycobacterium neoaurum* infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis. *Front Immunol.* 2022;13:972302. <https://doi.org/10.3389/fimmu.2022.972302>
- van Duin D, Goldfarb J, Schmitt SK, Tomford JW, Tuohy MJ, Hall GS. Nontuberculous mycobacterial blood stream and cardiac infections in patients without HIV infection. *Diagn Microbiol Infect Dis.* 2010;67:286-90. <https://doi.org/10.1016/j.diagmicrobio.2010.02.006>
- Walayat S, Awwal T, Roy M, Ahmad S. *Mycobacterium neoaurum* line-related bacteremia with pulmonary involvement: case report and review of literature. *IDCases.* 2018;11:88-90. <https://doi.org/10.1016/j.idcr.2018.01.004>
- Woo PC, Tsoi HW, Leung KW, Lum PN, Leung AS, Ma CH, et al. Identification of *Mycobacterium neoaurum* isolated from a neutropenic patient with catheter-related bacteremia by 16S rRNA sequencing. *J Clin Microbiol.* 2000;38:3515-7. <https://doi.org/10.1128/JCM.38.9.3515-3517.2000>
- Becker ML, Suchak AA, Wolfe JN, Zarychanski R, Kabani A, Nicolle LE. *Mycobacterium neoaurum* bacteremia in a hemodialysis patient. *Can J Infect Dis.* 2003;14:45-8. <https://doi.org/10.1155/2003/840103>
- Kim CK, Choi SI, Jeon BR, Lee YW, Lee YK, Shin HB. Pulmonary infection caused by *Mycobacterium neoaurum*: the first case in Korea. *Ann Lab Med.* 2014;34:243-6. <https://doi.org/10.3343/alm.2014.34.3.243>
- Morimoto Y, Chan ED, Heifets L, Routes JM. Pulmonary infection with *Mycobacterium neoaurum* identified by 16S ribosomal DNA sequence. *J Infect.* 2007;54:e227-31. <https://doi.org/10.1016/j.jinf.2006.12.010>
- Bastón-Paz N, Bolaños-Rivero M, Hernández-Cabrera M, Martín-Sánchez AM. Pacemaker infection with *Mycobacterium neoaurum* [in Spanish]. *Rev Esp Quimioter.* 2018;31:379-82.
- Kusano T, Fukasawa C, Yamamoto S, Shiratori E, Murata S, Takaki A, et al. Pin tract infection caused by *Mycobacterium neoaurum* in a 14-year-old child: a case report. *J Infect Chemother.* 2021;27:1244-7. <https://doi.org/10.1016/j.jiac.2021.03.005>
- McNally CF, Mangino JE. *Mycobacterium neoaurum*: a case report and review of the literature. *Infect Dis Clin Pract.* 2000;9:273-5. <https://doi.org/10.1097/00019048-200009060-00013>
- Zanetti S, Faedda R, Fadda G, Dupré I, Molicotti P, Ortu S, et al. Isolation and identification of *Mycobacterium neoaurum* from a patient with urinary infection. *New Microbiol.* 2001;24:189-92.
- Pérez-Cortés Villalobos A, Rotstein C. *Mycobacterium mucogenicum* and *Mycobacterium neoaurum* bacteremia in immunocompromised hosts. *J Assoc Med Microbiol Infect Dis Can.* 2021;6:55-62. [PubMed https://doi.org/10.3138/jammi-2020-0025](https://doi.org/10.3138/jammi-2020-0025)
- Redelman-Sidi G, Sepkowitz KA. Rapidly growing mycobacteria infection in patients with cancer. *Clin Infect Dis.* 2010;51:422-34. <https://doi.org/10.1086/655140>
- Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. *Clin Infect Dis.* 2020;71:905-13. <https://doi.org/10.1093/cid/ciaa1125>
- Philips RC, Hoyer PE, White SM, Tinkey KT, Loeffelholz M, Andersen CR, et al. Cutaneous nontuberculous mycobacteria infections: a retrospective case series of 78 patients from the Texas Gulf Coast region. *J Am Acad Dermatol.* 2019;81:730-9. <https://doi.org/10.1016/j.jaad.2019.04.022>
- Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Baretto R, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. *Lancet.* 2004;364:2113-21. [https://doi.org/10.1016/S0140-6736\(04\)17552-1](https://doi.org/10.1016/S0140-6736(04)17552-1)
- Heckman GA, Hawkins C, Morris A, Burrows LL, Bergeron C. Rapidly progressive dementia due to *Mycobacterium neoaurum* meningoencephalitis. *Emerg Infect Dis.* 2004;10:924-7. <https://doi.org/10.3201/eid1005.030711>


30. Han XY. *Mycobacterium neoaurum* contamination. Emerg Infect Dis. 2005;11:1316-7. <https://doi.org/10.3201/eid1108.040861>
31. Padya L, Chin'ombe N, Magwenzi M, Mbanga J, Ruhanya V, Nziramasanga P. Molecular identification of *Mycobacterium* species of public health importance in cattle in Zimbabwe by 16S rRNA gene sequencing. Open Microbiol J. 2015;9:38-42. <https://doi.org/10.2174/1874285801509010038>
32. Puk K, Guz L. Occurrence of *Mycobacterium* spp. in ornamental fish. Ann Agric Environ Med. 2020;27:535-9. <https://doi.org/10.26444/aaem/114913>
33. Sevilla IA, Molina E, Tello M, Elguezabal N, Juste RA, Garrido JM. Detection of mycobacteria by culture and DNA-based methods in animal-derived food products purchased at Spanish supermarkets. Front Microbiol. 2017;8:1030. <https://doi.org/10.3389/fmicb.2017.01030>
34. Desai AN, Hurtado RM. Infections and outbreaks of nontuberculous mycobacteria in hospital settings. Curr Treat Options Infect Dis. 2018;10:169-81. <https://doi.org/10.1007/s40506-018-0165-9>
35. Kaevska M, Sterba J, Svobodova J, Pavlik I. *Mycobacterium avium* subsp. *avium* and *Mycobacterium neoaurum* detection in an immunocompromised patient. Epidemiol Infect. 2014;142:882-5. <https://doi.org/10.1017/S0950268813001660>
36. Ransom EM, Alipour Z, Wallace MA, Burnham CA. Evaluation of optimal blood culture incubation time to maximize clinically relevant results from a contemporary blood culture instrument and media system. J Clin Microbiol. 2021;59:e02459-20. <https://doi.org/10.1128/JCM.02459-20>
37. Brown-Elliott BA, Woods GL. Antimycobacterial susceptibility testing of nontuberculous mycobacteria. J Clin Microbiol. 2019;57:e00834-19. <https://doi.org/10.1128/JCM.00834-19>
38. Huang WC, Yu MC, Huang YW. Identification and drug susceptibility testing for nontuberculous mycobacteria. J Formos Med Assoc. 2020;119:S32-41. <https://doi.org/10.1016/j.jfma.2020.05.002>
39. El Helou G, Viola GM, Hachem R, Han XY, Raad II. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis. 2013;13:166-74. [https://doi.org/10.1016/S1473-3099\(12\)70316-X](https://doi.org/10.1016/S1473-3099(12)70316-X)
40. Martín-de-Hijas NZ, García-Almeida D, Ayala G, Fernández-Roblas R, Gadea I, Celdrán A, et al. Biofilm development by clinical strains of non-pigmented rapidly growing mycobacteria. Clin Microbiol Infect. 2009;15:931-6. <https://doi.org/10.1111/j.1469-0691.2009.02882.x>
41. Brown-Elliott BA, Wallace RJ Jr, Petti CA, Mann LB, McGlasson M, Chihara S, et al. *Mycobacterium neoaurum* and *Mycobacterium bacteremicum* sp. nov. as causes of mycobacteremia. J Clin Microbiol. 2010;48:4377-85. <https://doi.org/10.1128/JCM.00853-10>
42. Ilinov A, Nishiyama A, Namba H, Fukushima Y, Takihara H, Nakajima C, et al. Extracellular DNA of slow growers of mycobacteria and its contribution to biofilm formation and drug tolerance. Sci Rep. 2021;11:10953. <https://doi.org/10.1038/s41598-021-90156-z>
43. Karol SE, Sun Y, Tang L, Pui CH, Ferrolino J, Allison KJ, et al. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Med. 2020;9:6550-5. <https://doi.org/10.1002/cam4.3249>

Address for correspondence: Elisabeth Adderson, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Mailstop 320, Memphis, TN 38120, USA; email: elisabeth.adderson@stjude.org

EID Podcast

The Mother of All Pandemics

Dr. David Morens, of the National Institute of Allergy and Infectious Diseases discusses the 1918 influenza pandemic.



Visit our website to listen:
<https://tools.cdc.gov/medialibrary/index.aspx#/media/id/393805>

EMERGING INFECTIOUS DISEASES®

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Healthcare-Associated Infections Caused by *Mycolicibacterium neoaurum*

Appendix

Appendix Table. Clinical characteristics and treatment of 37 reported cases of patients with *Mycolicibacterium neoaurum* infections*

No.	Age, y/sex, location	Medical condition, device duration†	Infection	Positive culture site, time to positive result	Treatment	Outcome	Reference
1	1/M, Missouri, USA	Acute lymphoblastic leukemia, subcutaneous port, 6 mo	Bacteremia, catheter-related	Port blood, 5 d	Port removed, IMI + AZI + CIP for 16 d, then TMS + CIP for 26 d	Cured	Case report
2	48/M, Michigan, USA	Acute lymphoblastic leukemia, subcutaneous port	Bacteremia, catheter-related	Blood, 5 d	Port removed, CIP + DOX for 3 mo	Cured	(1)
3	67/F, West Virginia, USA	Diabetes, chronic renal insufficiency, recurrent urinary tract infection, percutaneously inserted central line, 6 mo	Bacteremia, catheter-related	Catheter blood, 6 d	Central line removed, CIP + DOX for 4 wk	Not reported	(2)
4	41/M, Scotland, UK	Acute myeloid leukemia, neutropenia, central venous catheter	Bacteremia, catheter-associated	Catheter, peripheral blood	Central line removed, MER (duration not reported)	Cured	(3)
5	54/F, Queensland, Australia	Ovarian carcinoma, total parenteral nutrition, central venous catheter	Bacteremia, catheter-associated	Catheter, peripheral blood, 2–5 d	GEN + CEFO for 7 wk	Cured	(4)
6	31/F, Cadiz, Spain	Ulcerative colitis, peripheral intravenous catheter, 1 wk	Bacteremia, catheter-associated, exit site inflammation	Peripheral blood, 3 d	TEI for 7 d	Cured	(5)
7	46/M, Iowa, USA	Primary hyperparathyroidism, central venous catheter, 10 mo	Bacteremia, catheter-related	Catheter blood, 2 d	Catheter removed	Cured	(6)
8	48/M, Illinois, USA	Crohn's disease, short gut syndrome, hepatitis C infection, central venous catheter	Bacteremia, catheter-related	Blood	Catheter removed, IMI + CIP, then LEV for 4 wk	Cured	(7)
9	17/M, New South Wales, Australia	Acute lymphoblastic leukemia, hematopoietic stem cell transplant, neutropenia, central venous catheter	Bacteremia, catheter-related, catheter exit site inflammation	Catheter blood, 2 d	Catheter removed, TCL + TOB for 3 wk	Cured	(8)
10	46/M, Taiwan, China	Diabetes, alcohol-related pancreatitis and hepatitis, multi-organ failure, intra-abdominal infection, prosthetic joint replacement, hepatitis B infection, cerebrovascular accident, central venous catheter	Bacteremia, catheter-associated	Catheter blood, 6 d	Catheter removed, AMI + CIP for 1 wk, then AMI + MER for 2 wk	Cured	(9)

No.	Age, y/sex, location	Medical condition, device duration†	Infection	Positive culture site, time to positive result	Treatment	Outcome	Reference
11	66/M, Oklahoma, USA	Diabetes, colon cancer, schizophrenia, subcutaneous port, 6 y	Bacteremia, catheter-associated	Central, peripheral blood, catheter tip, 5 d	Port removed, DOX + IMI + LEV for 4 wk, then DOX + LEV for 2 wk	Cured	(10)
12	53/M, Pennsylvania, USA	Hepatocellular carcinoma, hepatitis B infection, psoriasis, subcutaneous port	Bacteremia, catheter-related	Catheter blood, 7 d	CON, unspecified duration	Relapsed 3 mo, port removed, CON for 2 wk, cured	(11)
13	4/F, Ohio, USA	Acute myeloid leukemia, central venous catheter	Bacteremia, catheter-associated	Blood	Catheter removed, TMS for 6 wk	Cured	(12)
14	39/F, Ohio, USA	Aplastic anemia, central venous catheter	Bacteremia, catheter-associated	Blood	Catheter removed, CIP + CEFT + ERY + ETH + RIF + CEFT for 6 wk	Cured	(12)
15	68/M, Illinois, USA	Diabetes, recurrent small bowel obstruction, parenteral nutrition, recurrent urinary tract infection, central venous catheter, 3 y	Bacteremia, catheter-related, pneumonia	Blood, catheter tip, 8 d	Catheter removed, CEFO + CIP + DOX for 6 wk, then CIP + DOX for 3 wk	Cured	(13)
16	1/F, Michigan, USA	Liver transplant	Bacteremia	Peripheral blood, 6 d	None	Cured	(14)
17	2/F, Michigan, USA	Neuroblastoma, neutropenia, central venous catheter, 5 mo	Bacteremia, catheter-associated	Blood, 4 d	Catheter removed, AMI + CLA + MER for 7 d, then CIP + LIN for 14 d	Cured	(14)
18	3/M, Michigan, USA	Rhabdomyosarcoma, neutropenia, central venous catheter, 7 mo	Blood, catheter-associated	Blood, 1 d	Catheter removed, AMI + CLA + LEV for 12 d, then CLA + LEV for 4 wk	Cured	(14)
19	59/F, Michigan, USA	Colon cancer, colectomy, short gut syndrome, percutaneously inserted central line, 1 mo	Blood, catheter-associated	Blood, 2 d	Catheter removed, CEFO for 2 wk, then CLA + ETHA + LEV for 4 wk	Cured	(14)
20	9/F, Hong Kong, China	Acute lymphoblastic leukemia, central venous catheter	Bacteremia, catheter-related	Catheter blood, 3 d	Catheter removed, CEFZ + AMI for 3 wk	Cured	(15)
21	40/F, Manitoba, Canada	Diabetes, chronic renal insufficiency, hepatitis C infection, hemodialysis fistula, 9 mo	Bacteremia	Blood, hemodialysis fistula, peripheral, excised graft	Excision hemodialysis fistula, CIP + DOX for 4 wk	Cured	(16)
22	80/F, England, UK	Heart block, pacemaker, 2 y	Bacteremia, pacemaker-associated infection	Blood, pacemaker leads, 4 d	Pacemaker removed, AMI + IMI for 23 d, then CIP + DOX + LIN for 1 mo, then CIP + DOX for 2 mo	Cured	(17)
23	30/M, Connecticut, USA	Intravenous drug abuse, endocarditis, prosthetic mitral valve replacement, 1 y	Prosthetic valve endocarditis, brain abscess	Blood, 10 d	AZI + MOX + TOB for 39 d, then AZI + ETH + MOX, duration not reported	Cured	(18)
24	36/M, Ohio, USA	Intravenous drug abuse, prosthetic mitral valve replacement, 1 y	Prosthetic valve endocarditis	Blood, mitral valve	Mitral valve replacement, CIP + IMI + TMS for 6 wk, then CIP + TMS suppression	Cured	(12)
25	63/F, Ontario, Canada	Cerebrovascular accident, rheumatoid arthritis, hypertension, corticosteroid use, tobacco smoker	Granulomatous meningitis	Broad range PCR, brain tissue	None	Death	(19)
26	17/M, Moravia, Czech Republic	Hodgkin lymphoma, malignant pleural effusion, neutropenia	Pneumonia	Sputum	CIP for 3 mo	Cured	(20)

No.	Age, y/sex, location	Medical condition, device duration†	Infection	Positive culture site, time to positive result	Treatment	Outcome	Reference
27	25/F, Chungcheong, South Korea	None	Pneumonia	Bronchoalveolar lavage fluid, 4 d	CLA for 4 mo	Cured	(21)
28	59/M, New South Wales, Australia	Emphysema, tobacco smoker, tuberculosis	Pneumonia	Sputum	MOX + RIF + TMP/SMX for 6 mo	Cured	(22)
29	67/F, Wisconsin, USA	Asthma, corticosteroid use, gastroesophageal reflux, dental caries, tobacco smoker	Pneumonia	Lung biopsy	AMI + CLA for 6 mo	Cured	(23)
30	63/F, Gran Canaria, Spain	Heart block, pacemaker, 11 d, hypertension, hypothyroid, breast cancer	Surgical wound infection, pacemaker pocket	Wound exudate, 10 d	LEV for 2 wk, then DOX + LEV for 4 wk	Cured	(24)
31	14/F, Chiba, Japan	Orthopedic surgery, external fixator, 18 d	Pin exit site infection	Pin tract exudate, 3 d	CIP + MIN, then MIN + TMS for 6 mo	Cured	(25)
32	76/M, England, UK	Chronic renal insufficiency, hypertension, peripheral vascular disease	Soft tissue infection	PCR, skin biopsy	CIP + DOX for 6 mo	Cured	(26)
33	58/M, Hong Kong, China	Penetrating hand injury, sea water exposure, hypothyroidism	Soft tissue infection	Tissue biopsy	Soft tissue debridement, CIP + DOX for 12 wk	Cured	(27)
34	53/F, New South Wales, Australia	Mitral valve replacement, hypertension	Soft tissue infection	PCR, skin biopsy	MOX + ROX for 4 mo	Cured	(28)
35	45/F, New South Wales, Australia	Chronic renal insufficiency, peritoneal dialysis	Peritonitis	Peritoneal fluid	GEN + VAN, then AMI + PIP, no duration given	Cured	(29)
36	54/M, Ohio, USA	Diabetes, hypertension, chronic renal insufficiency, continuous ambulatory peritoneal dialysis	Peritonitis	Peritoneal fluid	Dialysis catheter removed, AMI + CIP + RIF for 4 wk, then CIP + RIF for 3 mo	Cured	(30)
37	63/F, Sardinia, Italy	Chronic renal insufficiency, nephrolithiasis, recurrent urinary tract infection	Urinary tract infection	Urine, 6 d	Not reported	Cured	(31)

*AMI, amikacin; AZI, azithromycin; CEFO, ceftioxin; CEFT, ceftriaxone; CEFZ, ceftazidime; CIP, ciprofloxacin; CLA, clarithromycin; CON, contezolid; DOX, doxycycline; ERY, erythromycin; ETHA, ethambutol; GEN, gentamicin; IMI, imipenem; LEV, levofloxacin; LIN, linezolid; MER, meropenem; MIN, minocycline; MOX, moxifloxacin; PIP, piperacillin; RIF, rifampin; ROX, roxithromycin; TCL, ticarcillin-clavulanate; TEI, teicoplanin; TMS, trimethoprim-sulfamethoxazole; TOB, tobramycin; VAN, vancomycin.

†Medical conditions included the use of medical devices and duration of use, if reported.

References

- Alhousseini M, Miceli MH, Chandrasekar P, Revankar S. Catheter-related bloodstream infection due to *Mycobacterium neoaurum* in a patient with acute leukemia. *Leuk Lymphoma*. 2014;55:1933–4. [PubMed https://doi.org/10.3109/10428194.2013.858153](https://doi.org/10.3109/10428194.2013.858153)
- Awadh H, Mansour M, Shorman M. Bacteremia with an unusual pathogen: *Mycobacterium neoaurum*. *Case Rep Infect Dis*. 2016;2016:5167874. [PubMed https://doi.org/10.1155/2016/5167874](https://doi.org/10.1155/2016/5167874)

3. Baird SF, Taori SK, Dave J, Willocks LJ, Roddie H, Hanson M. Cluster of nontuberculous mycobacteraemia associated with water supply in a haemato-oncology unit. *J Hosp Infect.* 2011;79:339–43. [PubMed https://doi.org/10.1016/j.jhin.2011.07.006](https://doi.org/10.1016/j.jhin.2011.07.006)
4. Davison MB, McCormack JG, Blacklock ZM, Dawson DJ, Tilse MH, Crimmins FB. Bacteremia caused by *Mycobacterium neoaurum*. *J Clin Microbiol.* 1988;26:762–4. [PubMed https://doi.org/10.1128/jcm.26.4.762-764.1988](https://doi.org/10.1128/jcm.26.4.762-764.1988)
5. Rubia MF, Chozas N, García-Martos P, Reyes F. *Mycobacterium neoaurum* bacteremia in an immunodepressed patient [in Spanish] *Enferm Infecc Microbiol Clin.* 2009;27:58–9. [PubMed https://doi.org/10.1016/j.eimc.2008.02.003](https://doi.org/10.1016/j.eimc.2008.02.003)
6. George SL, Schlesinger LS. *Mycobacterium neoaurum*—an unusual cause of infection of vascular catheters: case report and review. *Clin Infect Dis.* 1999;28:682–3. [PubMed https://doi.org/10.1086/517216](https://doi.org/10.1086/517216)
7. Hawkins C, Qi C, Warren J, Stosor V. Catheter-related bloodstream infections caused by rapidly growing nontuberculous mycobacteria: a case series including rare species. *Diagn Microbiol Infect Dis.* 2008;61:187–91. [PubMed https://doi.org/10.1016/j.diagmicrobio.2008.01.004](https://doi.org/10.1016/j.diagmicrobio.2008.01.004)
8. Holland DJ, Chen SC, Chew WW, Gilbert GL. *Mycobacterium neoaurum* infection of a Hickman catheter in an immunosuppressed patient. *Clin Infect Dis.* 1994;18:1002–3. [PubMed https://doi.org/10.1093/clinids/18.6.1002](https://doi.org/10.1093/clinids/18.6.1002)
9. Lai CC, Tan CK, Chen CC, Hsueh PR. *Mycobacterium neoaurum* infection in a patient with renal failure. *Int J Infect Dis.* 2009;13:e276–8. [PubMed https://doi.org/10.1016/j.ijid.2008.11.001](https://doi.org/10.1016/j.ijid.2008.11.001)
10. Moseley JE Jr, Thind SK. *Mycobacterium neoaurum* bloodstream infection associated with a totally implanted subclavian port in an adult with diabetes and history of colon cancer. *Case Rep Infect Dis.* 2020;2020:8878069. [PubMed https://doi.org/10.1155/2020/8878069](https://doi.org/10.1155/2020/8878069)
11. Pang L, Chen Z, Xu D, Cheng W. Case report: *Mycobacterium neoaurum* infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis. *Front Immunol.* 2022;13:972302. [PubMed https://doi.org/10.3389/fimmu.2022.972302](https://doi.org/10.3389/fimmu.2022.972302)
12. van Duin D, Goldfarb J, Schmitt SK, Tomford JW, Tuohy MJ, Hall GS. Nontuberculous mycobacterial blood stream and cardiac infections in patients without HIV infection. *Diagn Microbiol Infect Dis.* 2010;67:286–90. [PubMed https://doi.org/10.1016/j.diagmicrobio.2010.02.006](https://doi.org/10.1016/j.diagmicrobio.2010.02.006)

13. Walayat S, Awwal T, Roy M, Ahmad S. *Mycobacterium neoaurum* line-related bacteremia with pulmonary involvement: case report and review of literature. IDCases. 2018;11:88–90. [PubMed https://doi.org/10.1016/j.idcr.2018.01.004](https://doi.org/10.1016/j.idcr.2018.01.004)
14. Washer LL, Riddell J 4th, Rider J, Chenoweth CE. *Mycobacterium neoaurum* bloodstream infection: report of 4 cases and review of the literature. Clin Infect Dis. 2007;45:e10–3. [PubMed https://doi.org/10.1086/518891](https://doi.org/10.1086/518891)
15. Woo PC, Tsoi HW, Leung KW, Lum PN, Leung AS, Ma CH, et al. Identification of *Mycobacterium neoaurum* isolated from a neutropenic patient with catheter-related bacteremia by 16S rRNA sequencing. J Clin Microbiol. 2000;38:3515–7. [PubMed https://doi.org/10.1128/JCM.38.9.3515-3517.2000](https://doi.org/10.1128/JCM.38.9.3515-3517.2000)
16. Becker ML, Suchak AA, Wolfe JN, Zarychanski R, Kabani A, Nicolle LE. *Mycobacterium neoaurum* bacteremia in a hemodialysis patient. Can J Infect Dis. 2003;14:45–8. [PubMed https://doi.org/10.1155/2003/840103](https://doi.org/10.1155/2003/840103)
17. Hayton ER, Koch O, Scarborough M, Sabharwal N, Drobniewski F, Bowler ICJW. Rapidly growing mycobacteria as emerging pathogens in bloodstream and device-related infection: a case of pacemaker infection with *Mycobacterium neoaurum*. JMM Case Rep. 2015;2:1–3. <https://doi.org/10.1099/jmmcr.0.000054>
18. Kumar A, Pazhayattil GS, Das A, Conte HA. *Mycobacterium neoaurum* causing prosthetic valve endocarditis: a case report and review of the literature. Braz J Infect Dis. 2014;18:235–7. [PubMed https://doi.org/10.1016/j.bjid.2013.05.012](https://doi.org/10.1016/j.bjid.2013.05.012)
19. Heckman GA, Hawkins C, Morris A, Burrows LL, Bergeron C. Rapidly progressive dementia due to *Mycobacterium neoaurum* meningoencephalitis. Emerg Infect Dis. 2004;10:924–7. [PubMed https://doi.org/10.3201/eid1005.030711](https://doi.org/10.3201/eid1005.030711)
20. Kaevska M, Sterba J, Svobodova J, Pavlik I. *Mycobacterium avium* subsp. *avium* and *Mycobacterium neoaurum* detection in an immunocompromised patient. Epidemiol Infect. 2014;142:882–5. [PubMed https://doi.org/10.1017/S0950268813001660](https://doi.org/10.1017/S0950268813001660)
21. Kim CK, Choi SI, Jeon BR, Lee YW, Lee YK, Shin HB. Pulmonary infection caused by *Mycobacterium neoaurum*: the first case in Korea. Ann Lab Med. 2014;34:243–6. [PubMed https://doi.org/10.3343/alm.2014.34.3.243](https://doi.org/10.3343/alm.2014.34.3.243)
22. Josan E, Singh S, Bark C, Infeld M. *Mycobacterium neoaurum* with isolated cavitary pulmonary infection. Chest. 2020;158:A370. <https://doi.org/10.1016/j.chest.2020.08.365>

23. Morimoto Y, Chan ED, Heifets L, Routes JM. Pulmonary infection with *Mycobacterium neoaurum* identified by 16S ribosomal DNA sequence. J Infect. 2007;54:e227–31. [PubMed https://doi.org/10.1016/j.jinf.2006.12.010](https://doi.org/10.1016/j.jinf.2006.12.010)
24. Bastón-Paz N, Bolaños-Rivero M, Hernández-Cabrera M, Martín-Sánchez AM. Pacemaker infection with *Mycobacterium neoaurum* [in Spanish]. Rev Esp Quimioter. 2018;31:379–82. [PubMed](https://doi.org/10.1016/j.jiac.2021.03.005)
25. Kusano T, Fukasawa C, Yamamoto S, Shiratori E, Murata S, Takaki A, et al. Pin tract infection caused by *Mycobacterium neoaurum* in a 14-year-old child: a case report. J Infect Chemother. 2021;27:1244–7. [PubMed https://doi.org/10.1016/j.jiac.2021.03.005](https://doi.org/10.1016/j.jiac.2021.03.005)
26. Chadha M, Arias M, Maxwell-Scott H, Creamer D, Boissiere J, Sioletic S, et al. *Mycobacterium neoaurum* as an unusual cause of skin and soft tissue infection. Int J Dermatol. 2023;62:e45–7. [PubMed https://doi.org/10.1111/ijd.16424](https://doi.org/10.1111/ijd.16424)
27. Omoruyi OJ, Ip WY, To KK. Hand infection due to *Mycobacterium neoaurum*. J Hand Surg Eur Vol. 2012;37:574–5. [PubMed https://doi.org/10.1177/1753193412442296](https://doi.org/10.1177/1753193412442296)
28. Martin LK, Lawrence R, Kossard S, Murrell DF. Cutaneous *Mycobacterium neoaurum* infection causing scarring alopecia in an immunocompetent host. Br J Dermatol. 2007;157:204–6. [PubMed https://doi.org/10.1111/j.1365-2133.2007.07953.x](https://doi.org/10.1111/j.1365-2133.2007.07953.x)
29. Jiang SH, Roberts DM, Clayton PA, Jardine M. Nontuberculous mycobacterial PD peritonitis in Australia. Int Urol Nephrol. 2013;45:1423–8. [PubMed https://doi.org/10.1007/s11255-012-0328-4](https://doi.org/10.1007/s11255-012-0328-4)
30. McNally CF, Mangino JE. *Mycobacterium neoaurum*: a case report and review of the literature. Infect Dis Clin Pract. 2000;9:273–5. <https://doi.org/10.1097/00019048-200009060-00013>
31. Zanetti S, Faedda R, Fadda G, Dupré I, Molicotti P, Ortu S, et al. Isolation and identification of *Mycobacterium neoaurum* from a patient with urinary infection. New Microbiol. 2001;24:189–92. [PubMed](https://doi.org/10.1016/j.jinf.2006.12.010)